About
Johnson & Johnson Innovation - JJDC is the strategic venture capital arm of Johnson & Johnson, operating as one of the oldest and most established corporate venture groups in the life sciences sector since its founding in 1973. Based in New Brunswick, New Jersey with significant operations in Cambridge, Massachusetts, JJDC invests across the full spectrum of healthcare innovation—pharmaceuticals, medical devices, diagnostics, and consumer health—at all stages from seed-level startups through Series B and beyond. The fund's investment thesis is tightly aligned with Johnson & Johnson's broader scientific and commercial objectives, prioritizing transformative solutions for conditions including cancer and Alzheimer's disease. As of early 2026, JJDC maintains an active portfolio of approximately 120 to 130 companies, having made over 450 total investments in its history with disclosed portfolio value exceeding $978 million. Individual investments have ranged from $25 million checks (as evidenced by recent capital deployment to MeiraGTx) down to early-stage commitments. Leadership includes Tom Heyman as President, alongside venture investment professionals such as Asish Xavier (Vice President, Venture Investments since 2004) and V. Kadir Kadhiresan, PhD (Vice President with focus on medical devices and digital health since 2007). Portfolio companies have generated measurable exits and include two unicorn-stage companies. For founders, JJDC provides not only capital but operational support navigating the path to clinical validation and commercialization, leveraging Johnson & Johnson's regulatory expertise, manufacturing capabilities, and market access. For institutional and strategic stakeholders, JJDC serves as a window into emerging healthcare innovation and a means of accessing early-stage deal flow in high-impact therapeutic areas. The fund operates with a discipline emphasizing financial soundness alongside strategic alignment, collaborating across ecosystems including partnerships with Takeda Ventures and OrbiMed in initiatives like FutuRx.